Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS) May 5, 2017August 13, 2017 liorco70 http://d22fjzb79sfamb.cloudfront.net/MDS2017/fri/1200%20-%201330/Fri%201300.mp4 E.M. Stein (USA)